Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that have changed between versions will be highlighted in yellow, and the changes will be clearly marked as updated.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow, and the change will be clearly marked as updated.
| Field | Version v6-FR | Version v5-EN |
|---|---|---|
| Language | French (Updated) | English |
| Date Updated | 2020-10-28 | 2020-10-28 |
| Drug Identification Number | 02258595 | 02258595 |
| Brand name | HUMIRA VIAL | HUMIRA VIAL |
| Common or Proper name | HUMIRA (ADALIMUMAB) VIAL | HUMIRA (ADALIMUMAB) VIAL |
| Company Name | ABBVIE CORPORATION | ABBVIE CORPORATION |
| Ingredients | ADALIMUMAB | ADALIMUMAB |
| Strength(s) | 40MG | 40MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS | SUBCUTANEOUS |
| Packaging size | 2 x 0.8mL vial (40mg/0.8mL) | 2 x 0.8mL vial (40mg/0.8mL) |
| Anatomical Therapeutical Chemical (ATC) code | L04AB | L04AB |
| Anatomical Therapeutical Chemical (ATC) description | IMMUNOSUPPRESSANTS | IMMUNOSUPPRESSANTS |
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date | 2020-11-02 | 2020-11-02 |
| Actual discontinuation date | ||
| Remaining supply date | 2020-11-02 | 2020-11-02 |
| Discontinuation status | To be discontinued | To be discontinued |
| Discontinuation decision reversal | No | No |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | The HUMIRA 40mg vial will be phased out by November 2nd 2020. AbbVie has now introduced the new HUMIRA 20 mg pre-filled syringe for pediatric patients prescribed HUMIRA 20mg. HUMIRA 40mg in PEN and pre-filled syringe are still available for pediatric patients prescribed HUMIRA 40mg. | The HUMIRA 40mg vial will be phased out by November 2nd 2020. AbbVie has now introduced the new HUMIRA 20 mg pre-filled syringe for pediatric patients prescribed HUMIRA 20mg. HUMIRA 40mg in PEN and pre-filled syringe are still available for pediatric patients prescribed HUMIRA 40mg. |
| Health Canada comments |